Endocrine Abstracts

Background: Colorectal cancer is the third most common cancer in the UK this had led to development of the bowel cancer screening programmes (BCSPs). It is known that ileo-colonic NETs are increasing in incidence in part thought to be related to increased endoscopy. There are few epidemiological data on rectal or ileal NETs diagnosed in BCSPs. This study aims to identify the number of NETs diagnosed through the UK BCSP.Methods: UK bowel cancer colonoscop...

Introduction: Carcinoid heart disease (CHD) develops in patients with small bowel NETs with carcinoid syndrome. Currently NT-proBNP (NTP) is suggested as the best current biomarker to screen for CHD and monitor heart failure. A number of other markers have been investigated for heart failure, however, none of these have been explored in NET patients with CHD or carcinoid syndrome. Galectin-3 (GAL3) promotes fibroblast proliferation and correlates with worse outcomes in heart f...

Introduction: Patients with neuroendocrine neoplasia (NEN) may experience psychological distress related to secretory effects of the tumour. 5-hydroxyindoleacetic acid (5-HIAA) is a metabolite of serotonin, the most important secretory product in carcinoid syndrome. This study aims to determine if urine 5-HIAA levels correlate with health-related quality of life (HRQoL) in patients with NEN.Methods: A retrospective single-centre cohort study was conducte...

Introduction: Previously published UK Cancer Registry data showed incidence of Neuroendocrine Neoplasms rising between 2001 and 2015. This was higher than had been thought (Genus et al.). We report more recent data with more accurate coding (ICD-O-3).Aim: To analyse National Cancer Registration and Analysis Service (NCRAS) data on Neuroendocrine Neoplasias (NENs) in England including years 2015–2017.Methods: Public He...

Introduction: The aetiology of NENs vary; some are sporadic, others familial. An association between index NENs of the mid gut (ileum and colon) with subsequent colorectal primaries has been reported.Aim: We determined to evaluate the relationship between the diagnosis of an index primary malignancy and subsequent diagnosis of NEN.Methods: A population-based retrospective cohort study was under taken for persons with NEN diagnosis ...

Introduction: Incidence of neuroendocrine neoplasia (NEN) is rising worldwide. The National Cancer Registry and Analysis Service allows accurate study of NEN in England. Aim: Calculate incidence and prevalence of NEN in England from 1995-2018. Calculate site-specific survival with multivariate analysis. Method: A population-based retrospective cohort study was performed. Data requested from NCRAS were reviewed by a steering group r...

Introduction: Sex differences have been noted at different sites of Neuroendocrine Neoplasia in previous registry studies across different countries. Analysis of National Cancer Registry and Analysis Service (NCRAS) data can help to clarify the significance and importance of this factor in England. Aim: To examine neuroendocrine neoplasia incidence and survival by sex, site and stage. Method: A population-based, cohort study was pe...

Background: Patients with neuroendocrine neoplasms (NENs) may often develop other malignancies. This study aimed to identify the frequency at which these second non-NEN malignancies occurred in England.Methods: Data was extracted from the National Cancer Registration and Analysis Service (NCRAS) on all patients diagnosed with a NEN at one of eight NEN site groups between 2012-2018: appendix, caecum, colon, lung, pancreas, rectum, small intestine and stom...

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which frequently develop metastatic disease, represent an estimated 70% of NETs. There are limited treatment options with current standard therapies for well-differentiated aggressive grade 2 and grade 3 (Ki-67 index 15−55%) GEP-NETs; however, these may include somatostatin analogues; peptide receptor radionuclide therapy (PRRT); molecular targeted therapies (everolimus or sunitinib); chemotherapy; and ...

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent an estimated 70% of NETs. GEP-NETs frequently develop metastatic disease with limited treatment options. For well-differentiated high grade 2 and 3 GEP-NETs, current therapies include peptide receptor radionuclide therapy (PRRT), somatostatin analogues, chemotherapy, cytoreduction, and molecular targeted therapies (everolimus, sunitinib). PRRT uses radiolabeled somatostatin analogues to selectively t...